• Shanghai International Studies University, LL.B. (2010)
  • Vanderbilt University Law School, LL.M. (2011)


  • New York
  • People's Republic of China


  • Mandarin
  • Japanese

Aurora Zhang


Aurora Zhang is an associate in the firm’s Shanghai office. She counsels multinational clients on critical operational issues covering areas such as contract administration and enforcement and application procedures for licenses and business compliance. She has also advised start‐ups on cross-border corporate structuring, business formation, and capital funding. She monitors market access opportunities and the changing regulatory environment, conducts research to address regulatory barriers for market entry, and regularly advises clients in a variety of industries, including food and agriculture, manufacturing, pharmaceutical, and technology.

Prior to joining the firm’s Shanghai office, Aurora was an associate at multiple law firms, including a boutique law firm in New York, a top-tier PRC law firm in Shanghai, and the Shanghai office of a leading international law firm. She has extensive experience advising U.S.-based corporations in their business formation, expanding, and investment in China. She is a member of the firm’s multidisciplinary working group helping clients navigate the rapidly evolving business, legal, and operational issues associated with the COVID-19 pandemic. She also participated in a multi-jurisdictional investigation of a U.S. publicly traded company’s Asian and European operations that involved allegations of fraud, corruption, and violations of U.S. sanctions.

Aurora is bilingual in Mandarin and English. She also has basic knowledge in Japanese. Having spent years living in China, the United States of America, and Japan, she has a unique understanding of cultural sensitivity, cross-cultural communication, and interactions on a day-to-day basis and in business settings. In addition, Aurora serves as a mentor, appointed by the Dean of Shanghai International Studies University Law School, for legal practice, career planning, and legal English study programs.


Admitted to practice: New York and People's Republic of China

Representative Matters

  • Advising several transnational corporations on compliance with U.S. and China regulations and providing guidance for their legal and operational issues associated with the COVID-19 pandemic.
  • Advised a leading manufacturer of packaging components and healthcare products in its business operation and transactions in China, Hong Kong and Singapore, including commercial contract review and regulatory compliance assistance.
  • Advised a world leading headwear manufacturer in its commercial franchise matters in China.
  • Advised a U.S. based bamboo products manufacturing company in its strategic investment projects in China.
  • Advised a leading high-end condiment production company on all aspects of market entry and business compliance issues, including corporate structure design, e-commerce strategies, joint venture negotiations, and employment issues.
  • Advised a top-tier multinational technology company in its acquisition of a NEEQ listed PRC seafood company.
  • Advised Goldman Sachs in its pre-IPO investment in a large multinational restaurant chain.
  • Advised a private equity fund in its financing projects for a leading PRC fresh food products e-commerce provider.
  • Advised a leading global food manufacturing company in its business expansion and investment in China.
  • Advised a PRC listed company in its acquisition of several U.S. based garment manufacturers.
  • Advised a Swedish listed company in its acquisition of a PRC leading dispenser development and manufacturing company.
  • Represented a PRC marine technology corporation in its strategic joint venture projects in China, Australia, and Dubai.
  • Provided legal counsel to several transnational corporations for their business transaction and investment projects in China, including a U.S. based fresh berry products supplier and a leading global food manufacturing company.
  • Assisted in the investigation of China operations of a publicly traded U.S. healthcare company involving potential ethical, civil, and criminal liability arising from whistleblower allegations.

Client Alerts & Newsletters